Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INVAGESIC FORTE vs ANEXSIA 5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.
Management of mild to moderate pain,Off-label: acute pain, dental pain, postoperative pain
Management of moderate to moderately severe pain where an opioid analgesic is appropriate
One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal half-life: 2-3 hours (prolonged in renal impairment; clinical context: requires dosing interval adjustment in Cr Cl <30 m L/min)
Oxycodone: terminal half-life 3.2-4.3 hours (immediate-release); prolonged in hepatic impairment. Acetaminophen: terminal half-life 2-3 hours (therapeutic doses); prolonged in hepatic impairment or overdose.
Codeine is metabolized via CYP2D6 to morphine, and via CYP3A4 to norcodeine. Ibuprofen is metabolized primarily via CYP2C9.
Hydrocodone: primarily hepatic via CYP3A4 and CYP2D6 to active metabolites (hydromorphone). Acetaminophen: hepatic metabolism via conjugation (glucuronidation, sulfation) and CYP2E1-mediated oxidation to toxic NAPQI.
Renal: 90% (70% unchanged, 20% as glucuronide conjugate); Fecal/biliary: <5%
Oxycodone: renal excretion of metabolites (conjugated and unconjugated) and parent drug; ~10% excreted unchanged. Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates); ~2-4% excreted unchanged.
99% (primarily albumin; binding reduced in hypoalbuminemia, uremia, and neonates)
Oxycodone: 38-45% bound to albumin and alpha-1-acid glycoprotein. Acetaminophen: 10-25% bound to albumin at therapeutic concentrations.
0.1-0.2 L/kg (clinical meaning: low Vd indicates limited extravascular distribution, consistent with high protein binding and acidic drug nature)
Oxycodone: Vd 2.0-3.0 L/kg; distributes extensively into tissues. Acetaminophen: Vd 0.8-1.0 L/kg; relatively uniform distribution.
Oral: 80-100% (food delays absorption but does not reduce extent)
Oxycodone: oral bioavailability 60-87% (immediate-release). Acetaminophen: oral bioavailability 88-98% (therapeutic doses).
Contraindicated in severe renal impairment (e GFR < 30 m L/min/1.73 m²). For moderate impairment (e GFR 30-59 m L/min/1.73 m²): use lowest effective dose, maximum 4 tablets per day; avoid in dialysis.
GFR 30-50 m L/min: use with caution, increase dosing interval to every 6 hours; GFR <30 m L/min: avoid use due to hydrocodeone accumulation.
Contraindicated in Child-Pugh class C (severe hepatic impairment). For class B (moderate): reduce dose by 50% and monitor; do not exceed 4 tablets per day. Class A (mild): no adjustment but caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: contraindicated.
Not recommended for pediatric patients under 18 years of age due to risk of serious adverse effects.
Not recommended for children under 18 years due to risk of respiratory depression.
Start at lower end of dosing range (e.g., 1 tablet every 6 hours); maximum 4 tablets per day. Avoid in patients with creatinine clearance < 30 m L/min. Monitor for renal function, hepatic function, and gastrointestinal bleeding.
Start with lowest dose (1 tablet every 6 hours), monitor renal and hepatic function, and avoid in frail elderly due to increased fall and cognitive impairment risk.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); neonatal opioid withdrawal syndrome; risk from concomitant use with benzodiazepines or other CNS depressants; cytochrome P450 2D6 ultra-rapid metabolizers (risk of life-threatening respiratory depression from codeine).
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from acetaminophen overdose.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; ultra-rapid metabolism of codeine (CYP2D6); gastrointestinal bleeding (NSAIDs); cardiovascular thrombotic events; renal toxicity; hepatic impairment; elderly patients; pregnancy.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity; adrenal insufficiency; severe hypotension; gastrointestinal obstruction; seizure; and serotonin syndrome.
Hypersensitivity to codeine, ibuprofen, or any component; patients with significant respiratory depression; acute or severe bronchial asthma (in an unmonitored setting or without resuscitative equipment); gastrointestinal bleeding; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery; children <12 years old; breastfeeding (ultra-rapid metabolizers of codeine).
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; severe hepatic impairment; and concurrent use of MAOIs within 14 days.
Avoid grapefruit juice as it may increase tramadol levels. High-fat meals may delay absorption but not overall effect. No specific dietary restrictions beyond avoiding alcohol.
Avoid alcohol. Grapefruit juice may enhance side effects; limit intake. Take with food to reduce gastrointestinal discomfort.
Pregnancy Category D for NSAID component (diclofenac): Avoid in third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. First and second trimester use associated with increased risk of miscarriage and cardiac malformations. Paracetamol component is generally considered low risk but chronic high doses may increase risk of fetal hepatotoxicity.
First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal renal toxicity, oligohydramnios, and premature closure of ductus arteriosus. Use only if clearly needed.
Diclofenac excreted in breast milk in low amounts (M/P ratio ~0.02-0.05); paracetamol M/P ratio ~1.0. Both considered compatible with breastfeeding at recommended doses. However, avoid if infant has hypersensitivity or G6PD deficiency. Monitor infant for sedation or respiratory depression if used with opioids.
Paracetamol and hydrocodone are excreted in breast milk. M/P ratio: paracetamol ~1.0, hydrocodone ~1.0-2.0. Use with caution; monitor infant for drowsiness and respiratory depression. Consider risk of infant sedation with long-term use.
Increased renal clearance in pregnancy may reduce plasma levels; however, dose adjustments are not recommended due to fetal safety concerns. Use lowest effective dose for shortest duration. Avoid NSAIDs after 20 weeks gestation; if necessary, reduce dose and limit duration.
Increased clearance in pregnancy may require dose adjustment. Monitor for pain control and adverse effects; no fixed dose change recommended. Consider lower starting dose due to potential fetal risks. Avoid chronic use; taper if possible.
Invagesic Forte (paracetamol 500 mg + tramadol 37.5 mg) is a fixed-dose combination analgesic. Tramadol is a prodrug requiring CYP2D6 metabolism; poor metabolizers may have reduced efficacy. Monitor for serotonin syndrome when used with SSRIs, SNRIs, or MAOIs. Maximum daily tramadol dose is 300 mg (8 tablets). Seizure risk increases in patients taking SSRIs, tricyclics, or with epilepsy.
ANEXSIA 5/325 contains hydrocodone 5 mg and acetaminophen 325 mg. Maximum acetaminophen dose from all sources should not exceed 4 g/day in adults; avoid in severe hepatic impairment. Hydrocodone is a Schedule II controlled substance with abuse potential; monitor for respiratory depression, especially in opioid-naive patients. Use with caution in patients with COPD, sleep apnea, or increased intracranial pressure. Consider naloxone co-prescription for high-risk patients. For acute pain, limit duration to 3-7 days.
Take exactly as prescribed; do not exceed 8 tablets daily.,May cause dizziness or drowsiness; avoid driving or operating machinery.,Avoid alcohol while taking this medication.,Do not take with other medications containing acetaminophen (paracetamol) to avoid liver damage.,Report severe constipation, nausea, or difficulty breathing to your doctor.,Do not stop abruptly; withdrawal symptoms may occur.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or other sedatives (e.g., benzodiazepines) while taking this medication.,Avoid other products containing acetaminophen (e.g., Tylenol, cold remedies) to prevent liver damage.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of others; dispose of unused medication via drug take-back programs.,Seek emergency help if you have trouble breathing, severe drowsiness, or signs of allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INVAGESIC FORTE vs ANEXSIA 5/325, answered by our medical review team.
INVAGESIC FORTE is a Opioid Analgesic Combination that works by Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.. ANEXSIA 5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INVAGESIC FORTE and ANEXSIA 5/325 depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INVAGESIC FORTE is: One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.. The standard adult dose of ANEXSIA 5/325 is: 1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INVAGESIC FORTE and ANEXSIA 5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INVAGESIC FORTE is classified as Category C. Pregnancy Category D for NSAID component (diclofenac): Avoid in third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. First and second trimester u. ANEXSIA 5/325 is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.